| Business Summary | | Tularik
Inc.
is
engaged
in
the
discovery
and
development
of
a
broad
range
of
orally
available
drugs
based
on
gene
regulation.
The
Company's
research
programs,
all
of
which
address
attractive
commercial
markets,
include
cancer,
cytomegalovirus,
diabetes,
obesity,
inflammation,
allergy/asthma,
lipid
disorders,
bacterial
diseases
and
a
class
of
drug
targets
called
orphan
nuclear
receptors.
Tularik
has
diversified
its
drug
discovery
and
development
efforts
not
only
across
a
large
number
of
diseases,
but
also
across
multiple
promising
targets
and
drug
candidates
for
these
diseases. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Tularik
Inc.,
engages
in
the
discovery
and
development
of
a
broadrange
of
novel
orally
available
drugs
based
on
gene
regulation.
For
the
six
months
ended
6/30/01,
revenues
rose
34%
to
$15.4
million.
Net
loss
before
acctg.
change
fell
6%
to
$21.1
million.
Revenues
reflect
collaborative
research
payments
from
Japan
Tabacco
and
Knoll
AG.
Lower
loss
was
partially
offset
by
an
increased
number
of
clinical
and
preclinical
studies
and
increased
headcount. | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| A. Heidrich III, 47 Chairman | -- | -- | David Goeddel, Ph.D., 48 CEO | $351K | $1.3M | Andrew Perlman, M.D., Ph.D., 52 Exec.
VP | 252K | 319K | Corinne Lyle, 39 VP,
CFO | -- | -- | William Rieflin, 39 VP,
Gen. Counsel and Sec. | 259K | -- | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|